Company intelligence / Profile preview

Liminal BioSciences Inc.

Belleville, Ontario, Canadaliminalbiosciences.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Liminal BioSciences is advancing its lead candidate LMNL6511, a GPR84 antagonist, to Phase 1 clinical trials. The company has also nominated LMNL6326 as its lead OXER1 antagonist candidate for eosinophil-driven diseases. Both programs are part of the company's focus on developing novel small molecule therapeutics targeting GPCRs for metabolic, inflammatory, and fibrotic diseases.

Therapeutic areas: GastroenterologyPulmonologyMetabolic DisordersNephrologyImmunologyEndocrinologyDermatologyRare Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

22 assets

plasminogen

Approved

21 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Liminal BioSciences Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liminal BioSciences Inc..

Explore the full profile